Escherichia infection – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:16:49 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Escherichia infection – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Immune Response of JNJ-78901563 and High-dose Influenza Vaccine in Preventing E. coli Infections in Adults Aged 65 and Older https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-jnj-78901563-and-high-dose-influenza-vaccine-in-preventing-e-coli-infections-in-adults-aged-65-and-older/ Wed, 29 Apr 2026 15:05:41 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-jnj-78901563-and-high-dose-influenza-vaccine-in-preventing-e-coli-infections-in-adults-aged-65-and-older/ This clinical trial is focused on studying the prevention of a disease caused by a type of bacteria known as Escherichia coli, specifically the kind that can cause serious infections outside the intestines. The study will also look at the effects of a high-dose flu vaccine. The trial involves two main treatments: a vaccine called ExPEC9V and a high-dose quadrivalent influenza vaccine, which is designed to protect against four different strains of the flu virus. The study will explore how these vaccines work when given together and separately in adults aged 65 years or older.

The purpose of the study is to evaluate the immune response, which is how the body defends itself against infections, to the flu vaccine when it is given with the ExPEC9V vaccine compared to when the flu vaccine is given alone. Participants will receive injections of these vaccines, and some may receive a placebo. The study will monitor the safety and any reactions to the vaccines, as well as how well the immune system responds to them.

Participants in the study will be monitored over a period of time to assess their immune response to the vaccines. This will involve checking the levels of antibodies, which are proteins the body makes to fight infections, in the blood. The study aims to provide valuable information on the effectiveness and safety of these vaccines in older adults, helping to improve prevention strategies for both Escherichia coli infections and influenza.

]]> Study on Ciprofloxacin’s Effect on Antibiotic Resistance in E. coli for Healthy Individuals https://clinicaltrials.eu/trial/study-on-ciprofloxacins-effect-on-antibiotic-resistance-in-e-coli-for-healthy-individuals/ Wed, 29 Apr 2026 15:05:41 +0000 https://clinicaltrials.eu/trial/study-on-ciprofloxacins-effect-on-antibiotic-resistance-in-e-coli-for-healthy-individuals/ This clinical trial is focused on studying antimicrobial resistance in a type of bacteria called Escherichia coli, commonly found in the human gut. The study will use a medication called Ciprofloxacin Kabi, which is a solution for infusion, to see if it can cause the bacteria to become resistant to antibiotics. The medication will be transformed into a syrup for oral use by mixing it with a liquid called SyrSpend SF.

The purpose of the study is to understand how low doses of ciprofloxacin might change the bacteria in the gut. Participants will be randomly assigned to receive either the ciprofloxacin syrup or a placebo. The study will monitor changes in the bacteria over a period of time to see if there is any shift in how the bacteria respond to the medication.

Participants will be involved in the study for a maximum of 28 days. During this time, the study will track the concentration of ciprofloxacin in the body and observe any changes in the bacteria. The goal is to gather information on whether the medication can lead to resistance in the bacteria, which is an important concern in treating infections.

]]>